Impact of vaccination on the incidence of measles in Mozambique in the period 2000 to 2011

The aim of this study was to contribute to the better planning of measles elimination actions in Mozambique, by considering the impact of vaccination actions over the period 2000 to 2011. Descriptive and ecological studies and case records made available by the Ministry of Health were used to analyz...

Descripción completa

Detalles Bibliográficos
Autores: Muloliwa, Artur Manuel, Camacho, Luiz Antonio Bastos, Verani, José Fernando Souza, Simões, Taynãna César, Dgedge, Martinho do Carmo
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2013
País:Brasil
Institución:Fundação Oswaldo Cruz (FIOCRUZ)
Repositorio:Cadernos de Saúde Pública
Idioma:inglés
OAI Identifier:oai:ojs.teste-cadernos.ensp.fiocruz.br:article/5191
Acceso en línea:https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/5191
Access Level:acceso abierto
Palabra clave:Measles
Vaccination
Immunization Coverage
Descripción
Sumario:The aim of this study was to contribute to the better planning of measles elimination actions in Mozambique, by considering the impact of vaccination actions over the period 2000 to 2011. Descriptive and ecological studies and case records made available by the Ministry of Health were used to analyze measles vaccination coverage. Statistical analysis was performed using time series and spatial analysis. Vaccine coverage rates ranged from 82% to 99%. Coverage rates in Maputo city were under 70% and in Niassa province they were over 100%. Coverage showed a clustered pattern in the districts. The measles incidence rate was 1.58 per 100,000 inhabitants (0.00-40.08 per 100,000 inhabitants); districts bordering neighboring countries presented high incidence rates. Although measles morbidity and mortality has decreased in Mozambique, vaccine coverage has been insufficient to interrupt measles transmission. Enhanced surveillance, including investigation of cases and outbreaks, and improvements in measles vaccination are recommended in order to achieve a homogenous coverage rate of ≥ 95% for both routine and mass vaccination campaigns.